Abstract:Background Immune checkpoint inhibitors have become a standard therapeutic approach for cancer patients. Despite their impressive effects in treating solid tumors in certain clinical applications, the overall response rate (ORR) remains limited, hindering its wider use. This is at least partially attributed to inefficient biodistribution of therapeutic agents and insufficient infiltration of T cells within tumor microenvironment (TME). Therefore, methods to enhance the therapeutic effects of ICB are in high demand. Methods In this work, we produced both murine and humanized programmed cell death protein 1 (PD-1) antibody iRGD conjugates (αPD-1-(iRGD)2) through glycoengineering and bio-orthogonal reaction. The antitumor efficacy of αPD-1-(iRGD)2 was examined in murine tumor models. Biosafety and TME modulation were evaluated with histology, flow cytometry and RNA sequencing. Results iRGD modification largely refined the penetration of both PD-1 mAb and T cells. Besides, αPD-1-(iRGD)2 engages T cells and tumor cells thus promoting tumor elimination, which is not achievable by single agent αPD-1 or combination therapy. αPD-1-(iRGD)2 selectively engages and activates PD-1+ T cells which contains more tumor specific clusters. Systemic administration of αPD-1-(iRGD)2 elicited TME remodulation and impressive tumor growth control in various mouse tumor models with different immune infiltration characteristics, indicating αPD-1-(iRGD)2 might have broad-spectrum antitumor potential. During the regimen, no weight loss or main organ damage was observed. Furthermore, αPD-1-(iRGD)2 expands a unique population of T cells expressing stem and memory associated genes, which have been previously linked to tumor regression induced by αPD-1-IL2 conjugate (Nature 610, 161–172), so called 'better effector'. Conclusions In this work, we found that αPD-1-(iRGD)2 could enhance therapeutic potential for cancer treatment by simultaneously engaging T cells and tumor cells, promoting T cell infiltration and expanding a unique population of 'better effector' T cells. αPD-1-(iRGD)2 has the potential to be a novel and promising therapeutic approach for cancer immunotherapy. Ethics Approval All animal experiments were approved by the Institutional Animal Care and Use Committee of Drum Tower Hospital (approval number: 2020AE01064).

A polymeric IDO inhibitor based on poly(ethylene glycol)-<i>b</i>-poly(l-tyrosine-<i>co</i>-1-methyl-d-tryptophan) enables facile trident cancer immunotherapy

Bimetallic Peroxide-Based Nanotherapeutics for Immunometabolic Intervention and Induction of Immunogenic Cell Death to Augment Cancer Immunotherapy

Integrated Combination Delivery of IDO Inhibitor and Paclitaxel for Cancer Treatment

Nano-encapsulated Tryptanthrin Derivative for Combined Anticancer Therapy Via Inhibiting Indoleamine 2,3-Dioxygenase and Inducing Immunogenic Cell Death.

IDO-inhibitor potentiated immunogenic chemotherapy abolishes primary tumor growth and eradicates metastatic lesions by targeting distinct compartments within tumor microenvironment

A Supramolecular “Trident” for Cancer Immunotherapy

Trinity immune enhancing nanoparticles for boosting antitumor immune responses of immunogenic chemotherapy

Polymersomal Poly(I:C) Self‐Magnifies Antitumor Immunity by Inducing Immunogenic Cell Death and Systemic Immune Activation

1197 Site-specific Anti-Pd-1-irgd Peptide Conjugate Boosts Antitumor Efficacy Via Enhancement of T Cell Penetration and Engagement

Polymeric nanocarrier via metabolism regulation mediates immunogenic cell death with spatiotemporal orchestration for cancer immunotherapy

A lipid/PLGA nanocomplex to reshape tumor immune microenvironment for Colon cancer therapy

Discovery of the First Potent IDO1/IDO2 Dual Inhibitors: A Promising Strategy for Cancer Immunotherapy

Polypeptide nanoformulation-induced immunogenic cell death and remission of immunosuppression for enhanced chemoimmunotherapy

Dual‐Responsive Supramolecular Polymeric Nanomedicine for Self‐Cascade Amplified Cancer Immunotherapy

Cure for the AA battery blues. Six-volt battery pack from previously discarded Polaroid batteries.

Stepwise Targeting and Tandem Responsive Peptide Nanoparticles Enhance Immunotherapy through Prolonged Drug Retention

Plasmon‐Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway

Redox-Activated Porphyrin-Based Liposome Remote-Loaded with Indoleamine 2,3-Dioxygenase (IDO) Inhibitor for Synergistic Photoimmunotherapy Through Induction of Immunogenic Cell Death and Blockage of IDO Pathway

Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors.

Copackaging Doxorubicin and PD‐L1 siRNA in Dual‐Responsive Covalent Organic Frameworks for Synergistic Cancer Chemoimmunotherapy

Phenolic immunogenic cell death nanoinducer for sensitizing tumor to PD-1 checkpoint blockade immunotherapy